Take stock of the 12 licensed innovative therapies introduced/licensed in July, such as Baiji and Howson.

In July, china's pharmaceutical companies continued to be active in licensing transactions.
at least 12 Chinese companies agreed to cooperate last month, according to incomplete statistics.
At the same time, Many companies such as Baiji Shenzhou, Pharmaceutical Ming Juno, Qilu Pharmaceuticals and other companies introduced products, Wantai Bio, Howson Pharmaceuticals, Baiotai and other Chinese companies have also realized the independent research and development of products licensed out.
this article, we've selected some of the most interesting licensing cases to see what innovative therapies and technologies are involved in these transactions.
1, Introduction: Baiji Shenzhou Licensee: Assembly Biosciences Drug Disease Field: Hepatitis B Baiji Shenzhou obtained three clinical phase core inhibitors for the treatment of chronic hepatitis B infection ABI-H07 in the Research and Development Pipeline of Asembly Biosciences 31, ABI-H2158 and ABI-H3733 exclusive development and commercialization rights in Greater China (including Chinese mainland, Hong Kong, Macau and Taiwan), Assembly reserves full rights to its hepatitis B research and development pipeline worldwide, except in the above-mentioned regions.
up to $540 million in advance and milestone payments for the deal.
according to the Baiji Shenzhou press release, all three hepatitis B small molecule candidates are core inhibitors for hepatitis B, which inhibits multiple steps in the life cycle of hepatitis B.
among them, ABI-H0731 is a generation of core inhibitors, in Phase 2 clinical trials, ABI-H0731 combined nucleoside (acid) analogo retrovirus inhibitors (NrtI) resistance is good, compared with NrtrI monotherapy, the inhibition of HBV DNA produced statistically significant antiviral activity, and significantly reduced pre-genome (PGRNA), which may also indicate a decrease in cyclic DNA (cccRNA).
ABI-H2158 and ABI-H3733 are two powerful second-generation drug candidates, which are in the phase 2 clinical and phase 1 clinical development stages.
2. Introduction: Drug Ming Juno Licensor: Acepodia Drug Type: Cell Immunotherapy Drug JW Therapeutics obtained exclusive priority authorization for clinical and commercialization in Chinese mainland, Hong Kong and Macau through an exclusive priority licensing cooperation agreement with Acepodia ( Yu Expo Biotechnology ) .
, ACE1702 is a cell therapy that targets HER2 and is currently in clinical trials by connecting natural killer cells (oNK) with HER2 antibodies to the expression of HER2.
according to the press release, Acepodia's isotocytotherapy platform is based on its proprietary off-the-shelf natural killer cells, which have strong anti-tumor activity.
Acepodia's proprietary ACC™ (Antibody Cell Complex) technology glues antibodies to the cell membrane proteins of ready-to-use oNK cells that have therapeutic potential for self-development to enhance the ability to kill tumor cells.
3. Introduction: Cytokinetics Drug Type: Myomyosin Inhibitor Cytokinetics Inc. and Cytokinetics Inc. have signed an exclusive license agreement for the development and commercialization of a new generation of cardiomyosoprotein inhibitor CK-274 in Greater China.
under the agreement, the company has committed to make an advance payment and a milestone payment required for an additional $200 million in research and development and commercialization, and will also pay Cytokinetics a double-digit sales credit for the product in the agreed area.
CK-274 is a new type of oral small molecule cardiomyosoprotein inhibitor developed independently by Cytokinetics scientists to reduce the high shrinkage of hypertrophomyopathy (HCM), according to a press release.
In preclinical models, CK-274 reduces myocardial contraction by binding directly with myomyocytolic protein at a unique and selective variant binding point, thereby preventing myoprotein from entering a contractionary state.
CK-274 reduced the number of active tyroin-myoglobin cross bridges per tcentric cycle, thereby reducing myocardial contraction.
mechanism may have therapeutic effects on diseases characterized by excessive contraction, such as HCM.
4. Importer: Reding Pharmaceutical Licensor: Turning Therapeutic Points Drug Type: ROS1/TRK Inhibitor Redding Pharma acquired exclusive development and commercialization rights for Turing Point's main candidate drug, reporcerectinib, in Greater China, with an advance and milestone payment totalling $176 million.
Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) under development to be developed to treat non-small cell lung cancer and advanced solid tumors caused by cancer-causing gene changes in ROS1 and TRK.
Currently, repotrectinib is conducting a Global Phase 2 registration study for adult patients and a Global Phase 1/2 study for child patients that shows that the drug has anti-tumor activity and long-lasting response in both patients who have not received TKI treatment and those who have been treated with TKI.
Photo Source: pexels 5, Introduction: Saisheng Pharmaceutical Licensing Party: EpicentRx Drug Type: Oncology Immunotherapy Target CD47-SIRP Alpha Sessyn Pharma introduced a tumor immunotherapy RRx-001 from EpicCentRx.
Under the agreement, Saisheng Pharma was granted exclusive license to jointly develop and commercialize RRx-001 for cancer treatment in Greater China, as well as an unrealized advance payment of up to $120 million to EpicentRx.
addition, Saisheng Pharmaceuticals has the option of developing a separate application of RRx-001 in hepatocellular carcinoma in Greater China.
According to the press release, RRx-001 targets CD47-SIRP alpha, which repolarizes tumor-related macrophages (TAM) and other immunosuppressive cells in the tumor micro-environment into immunostification espresso, and improves tumor blood flow to enhance oxygen supply and drug delivery.
as a potential immunotherapy that converts "therapeuticly suitable" tumors into "therapeuticly sensitive" tumors, RRx-001 can be used as a monotherapy or in combination with other drugs.
, RRx-001 is currently undergoing a Phase 3 clinical trial for the treatment of small cell lung cancer on the third line and above.
, EpicentRx plans to explore the drug's therapeutic effects in colorectal cancer, brain metastasis and glioma, leukemia, and myeloid abnormal progeny syndrome.
6, Introduction: Qilu Pharmaceutical Licensing Party: Sesen Bio Drug Type: Antibody Association Drug (ADC) Qilu Pharmaceuticals and Sesen Bio reached an exclusive licensing agreement to obtain the latter in the research of new drug Vicineum (oportuzumab monatox) exclusive production, development and commercialization interest in Greater China to develop the drug to treat non-muscle immersive bladder cancer (NMIBC) and other types of cancer that do not respond to BCG.
Sesen Bio reserves the full development and commercialization rights of Vicineum to treat NMIBC in the United States and other parts of the world except Greater China.
up to $35 million in advance and milestone payments for this transaction.
Vicinium is a next-generation antibody-coupled drug developed using Sesen Bio's proprietary targeted protein therapy platform that targets endotrine adhesive molecules (EpCAM) antigens on the surface of tumor cells to provide an effective protein load, prosthetic monocytotoxin A (ETA).
Vicinium is connected by stable genetically engineered peptides to ensure that payloads remain attached until they are internalized by cancer cells, reducing the risk of toxicity to healthy tissue and improving safety.
U.S., Vicinium has been granted orphan drug and fast-track eligibility by the FDA to treat NMIBC, which is ineffective against BCG immunotherapy.
December 2019, Sesen Bio has initiated a rolling submission of Vicinium's Biological Products Licensing Application (BLA) to the FDA.
7, the introduction of: Hansen Pharmaceutical Licensee: Tuoton Biopharmaceutical Type: BCR-ABL protein structure inhibitor Hansen Pharmaceuticals obtained the exclusive development and commercialization interests of Tuoton Bio TRN-000632 in Greater China, Torto Bio will retain the product development and commercialization interest in other markets around the world.
under the agreement, Torto Bio will receive a down payment of not more than $68 million, research and development, registration, sales milestone payments, and a future product sales-based credit.
TRN-000632 is a highly active BCR-ABL protein structure inhibitor that is being used to develop adaptations associated with chronic myeloid leukemia (CML).
8, Introducer: Sanofi Pasteur Licensor: Vantai Biological Drug Type: Rotavirus Vaccine Sanofi Pasteur Obtains Vantai, a wholly owned subsidiary of Vantai Bio Marine bio-licensing, the global development, production and commercialization of the latter's new rota virus vaccine, mainly for the prevention of diarrhea in children caused by type A rota virus, while The Wantai Bohai has the right to obtain the above-mentioned authorization from Sanofi Pasteur to develop rotavirus vaccine in China.
the total amount of advances and milestones for this transaction amounted to $68 million.
according to a press release, the rotovirus vaccine is one of the world's major vaccine varieties, the global market of the rotovirus vaccine mainly has unit-priced and multi-priced seedlings.
deal involves a new rotor virus recombinant protein vaccine that induces high-titular broad-spectrum protection antibodies against a variety of serotypes in animals.
9, Introducer: EQRx Licensee: Howson Pharmaceuticals Type: 3th Generation EGFR-TKI Henson (Shanghai) Health Technology and Howson Pharmaceuticals enter into strategic cooperation and licensing agreement with EQRx To award E QRx exclusive license to develop, produce and commercialize the former's third-generation EGFR-TKI Amedini (and any products containing or consisting of Amedini) outside China, covering therapeutic areas such as cancer, cancer-related and immuno-inflammatory diseases.
down payment, registration and development milestone payment for the transaction was approximately $100 million.
Amedini, a third-generation EGFR (skin growth factor inhibitor) -TKI (Tyrosine kinase inhibitor) developed by Howson Pharmaceuticals, was approved in China in March this year for the treatment of patients with local late stage or metastasis non-small cell lung cancer (NSCL) who have been treated with EGFR-TKI and are positive for the T790M mutation.
note that this is not only the first Chinese-made third-generation EGFR-TKI to be approved for listing, but also the second third-generation EGFR-TKI to be approved for listing worldwide.
10, Introduction: Pharmapark Licensor: Baiotai Drug Type: Golimu monobiobiotic similar drug Baiotai authorized Pharmapark company in Russia and other CIS countries exclusive commercialization of its Golimu single anti-biosynthic drug BAT2506.
golimumab is an all-humanized anti-tumor necrotizing factor (TNF-alpha) monoclonal antibody.
cooperation agreement, Baotte will be responsible for the development of bat2506 and the supply of commercial products to Pharmapark.
Pharmapark will be responsible for the pharmaceutical administration and commercialization of BAT2506 in Russia and other CIS countries.
the fourth quarter of this year, Baotai is expected to launch an international multi-center Phase 3 clinical trial of BAT2506 and recruit patients in China, Russia and several other countries, according to a press release.
the company plans to submit listing applications to China's NMPA, Europe's EMA and the U.S. FDA after completing Phase 3 clinical trials.
11. Introduction: Lingke Pharmaceutical Licensor: Kobe University, RIKEN Research Institute Drug Type: RAS Inhibitor Lingke Pharmaceuticals announces an exclusive licensing agreement with Kobe University in Japan and RIKEN Research Institute in Japan to develop RAS inhibitors with a new drug action mechanism (MOA).
According to the press release, Lingke Pharmaceuticals will use its pharmaceutical chemistry and drug design expertise to develop better RAS inhibitors based on the early structural biology and screening results of Kobe University and RIKEN to target a wider range of "non-essential" RAS mutation-induced malignancies and ultimately to develop clinically effective drugs.
12, Introduction: NewG Lab Pharma Licensor: Yanyuan Pharmaceutical Type: ROS1/NTRK Inhibitor NewG Lab Pharma Korea obtained the license of Yanyuan Pharmaceutical, in the Korean market for the former ROS1/NTRK inhibitor taletrectinib for exclusive clinical development and commercialization.
Under the agreement, Yanyuan Pharmaceuticals will receive a milestone payment of $7 million and double-digit royalties, and NewG Lab will be responsible for the development and commercialization of taletrectinib in Korea, while being allowed to participate in the drug's ongoing multi-region Phase 2 clinical trials for patients with ROS1/NTRK mutations in NSCLC.
Tallectrectinib is a new, effective and highly selective next-generation ROS1 and NTRK dual target.